Jun Yang1, Alaa M AlTahan1, Dongli Hu1, Yingdi Wang1, Pei-Hsin Cheng1, Christopher L Morton1, Chunxu Qu1, Amit C Nathwani1, Jason M Shohet1, Theodore Fotsis1, Jan Koster1, Rogier Versteeg1, Hitoshi Okada1, Adrian L Harris1, Andrew M Davidoff2. 1. Department of Surgery (JY, AMA, DH, PHC, CLM, AMD) and Department of Bioinformatics (CQ), St. Jude Children's Research Hospital, Memphis, TN; Yale Cardiovascular Research Center, Yale School of Medicine, New Haven, CT (YW); Department of Oncology, University College London Cancer Institute, London, UK (ACN); Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX (JMS); Division of Biomedical Research, Foundation of Research and Technology-Hellas, Institute of Molecular Biology and Biotechnology, Ioannina, Greece (TF); Laboratory of Biological Chemistry, Medical School, University of Ioannina, Ioannina, Greece (TF); Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands (JK, RV); Kinki University Faculty of Medicine, Osaka-Sayama, Osaka, Japan (HO); Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK (ALH). 2. Department of Surgery (JY, AMA, DH, PHC, CLM, AMD) and Department of Bioinformatics (CQ), St. Jude Children's Research Hospital, Memphis, TN; Yale Cardiovascular Research Center, Yale School of Medicine, New Haven, CT (YW); Department of Oncology, University College London Cancer Institute, London, UK (ACN); Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX (JMS); Division of Biomedical Research, Foundation of Research and Technology-Hellas, Institute of Molecular Biology and Biotechnology, Ioannina, Greece (TF); Laboratory of Biological Chemistry, Medical School, University of Ioannina, Ioannina, Greece (TF); Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands (JK, RV); Kinki University Faculty of Medicine, Osaka-Sayama, Osaka, Japan (HO); Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK (ALH). andrew.davidoff@stjude.org.
Abstract
BACKGROUND: Epigenetic alterations, such as histone methylation, modulate Myc signaling, a pathway central to oncogenesis. We investigated the role of the histone demethylase KDM4B in N-Myc-mediated neuroblastoma pathogenesis. METHODS: Spearman correlation was performed to correlate MYCN and KDM4B expression. RNA interference, microarray analysis, gene set enrichment analysis, and real-time polymerase chain reaction were used to define the functions of KDM4B. Immunoprecipitation and immunofluorescence were used to assess protein-protein interactions between N-Myc and KDM4B. Chromatin immunoprecipitation was used to assess the binding of Myc targets. Constitutive and inducible lentiviral-mediated KDM4B knockdown with shRNA was used to assess the effects on tumor growth. Kaplan-Meier survival analysis was used to assess the prognostic value of KDM4B expression. All statistical tests were two-sided. RESULTS: KDM4B and MYCN expression were found to be statistically significantly correlated in a variety of cancers, including neuroblastoma (R = 0.396, P < .001). Functional studies demonstrated that KDM4B regulates the Myc pathway. N-Myc was found to physically interact with and recruit KDM4B. KDM4B was found to regulate neuroblastoma cell proliferation and differentiation in vitro and xenograft growth in vivo (5 mice/group, two-tailed t test, P ≤ 0.001). Finally, together with MYCN amplification, KDM4B was found to stratify a subgroup of poor-prognosis patients (122 case patients, P < .001). CONCLUSIONS: Our findings provide insight into the epigenetic regulation of Myc via histone demethylation and proof-of-concept for inhibition of histone demethylases to target Myc signaling in cancers such as neuroblastoma.
BACKGROUND: Epigenetic alterations, such as histone methylation, modulate Myc signaling, a pathway central to oncogenesis. We investigated the role of the histone demethylase KDM4B in N-Myc-mediated neuroblastoma pathogenesis. METHODS: Spearman correlation was performed to correlate MYCN and KDM4B expression. RNA interference, microarray analysis, gene set enrichment analysis, and real-time polymerase chain reaction were used to define the functions of KDM4B. Immunoprecipitation and immunofluorescence were used to assess protein-protein interactions between N-Myc and KDM4B. Chromatin immunoprecipitation was used to assess the binding of Myc targets. Constitutive and inducible lentiviral-mediated KDM4B knockdown with shRNA was used to assess the effects on tumor growth. Kaplan-Meier survival analysis was used to assess the prognostic value of KDM4B expression. All statistical tests were two-sided. RESULTS: KDM4B and MYCN expression were found to be statistically significantly correlated in a variety of cancers, including neuroblastoma (R = 0.396, P < .001). Functional studies demonstrated that KDM4B regulates the Myc pathway. N-Myc was found to physically interact with and recruit KDM4B. KDM4B was found to regulate neuroblastoma cell proliferation and differentiation in vitro and xenograft growth in vivo (5 mice/group, two-tailed t test, P ≤ 0.001). Finally, together with MYCN amplification, KDM4B was found to stratify a subgroup of poor-prognosis patients (122 case patients, P < .001). CONCLUSIONS: Our findings provide insight into the epigenetic regulation of Myc via histone demethylation and proof-of-concept for inhibition of histone demethylases to target Myc signaling in cancers such as neuroblastoma.
Authors: Ivan Garcia-Bassets; Young-Soo Kwon; Francesca Telese; Gratien G Prefontaine; Kasey R Hutt; Christine S Cheng; Bong-Gun Ju; Kenneth A Ohgi; Jianxun Wang; Laure Escoubet-Lozach; David W Rose; Christopher K Glass; Xiang-Dong Fu; Michael G Rosenfeld Journal: Cell Date: 2007-02-09 Impact factor: 41.582
Authors: Charles Y Lin; Jakob Lovén; Peter B Rahl; Ronald M Paranal; Christopher B Burge; James E Bradner; Tong Ihn Lee; Richard A Young Journal: Cell Date: 2012-09-28 Impact factor: 41.582
Authors: Charles Chuanhai Guo; Vipulkumar Dadhania; Li Zhang; Tadeusz Majewski; Jolanta Bondaruk; Maciej Sykulski; Weronika Wronowska; Anna Gambin; Yan Wang; Shizhen Zhang; Enrique Fuentes-Mattei; Ashish Madhav Kamat; Colin Dinney; Arlene Siefker-Radtke; Woonyoung Choi; Keith A Baggerly; David McConkey; John N Weinstein; Bogdan Czerniak Journal: Eur Urol Date: 2016-03-15 Impact factor: 20.096
Authors: Jun Yang; Sandra Milasta; Dongli Hu; Alaa M AlTahan; Rodrigo B Interiano; Junfang Zhou; Jesse Davidson; Jonathan Low; Wenwei Lin; Ju Bao; Pollyanna Goh; Amit C Nathwani; Ruoning Wang; Yingdi Wang; Su Sien Ong; Vincent A Boyd; Brandon Young; Sourav Das; Anang Shelat; Yinan Wu; Zhenmei Li; Jie J Zheng; Ashutosh Mishra; Yong Cheng; Chunxu Qu; Junmin Peng; Douglas R Green; Stephen White; R Kiplin Guy; Taosheng Chen; Andrew M Davidoff Journal: Cancer Res Date: 2017-07-06 Impact factor: 12.701
Authors: Shivendra Singh; Ahmed Abu-Zaid; Hongjian Jin; Jie Fang; Qiong Wu; Tingting Wang; Helin Feng; Waise Quarni; Ying Shao; Lily Maxham; Alireza Abdolvahabi; Mi-Kyung Yun; Sivaraja Vaithiyalingam; Haiyan Tan; John Bowling; Victoria Honnell; Brandon Young; Yian Guo; Richa Bajpai; Shondra M Pruett-Miller; Gerard C Grosveld; Mark Hatley; Beisi Xu; Yiping Fan; Gang Wu; Eleanor Y Chen; Taosheng Chen; Peter W Lewis; Zoran Rankovic; Yimei Li; Andrew J Murphy; John Easton; Junmin Peng; Xiang Chen; Ruoning Wang; Stephen W White; Andrew M Davidoff; Jun Yang Journal: Sci Transl Med Date: 2022-07-13 Impact factor: 19.319
Authors: Arun Kanakkanthara; Larry M Karnitz; Thomas L Ekstrom; Nicholas M Pathoulas; Amelia M Huehls Journal: Mol Cancer Ther Date: 2021-06-17 Impact factor: 6.261